PATENT CLAIM ANALYSIS

Application Number: 16379559
Application Type: Utility
Filing Date: 2019-04
Publication Date: 2019-08
Patent Classification: ["424", "009100"]

Abstract:
The present subject matter is directed to a method of manufacturing and purifying an intravenous injection of prothrombin complex concentration (PCC) from plasma Fraction III and a method of manufacturing and purifying an intravenous injection of non-PCC from plasma Fraction IV. The intravenous injection of PCC and non-PCC obtained from the method can be administered to a patient in need thereof for stopping replication, killing and preventing HIV-1 and HIV-2 in a patient.

Claim (Index 11):
A method of treatment for a patient comprising administering the intravenous injection of PCC obtained from the method of  claim 1  to a patient in need thereof,\n wherein the intravenous injection of PCC transforms or repairs damaged and sick cells to become healthy cells, \n wherein the intravenous injection of PCC protects cellular alterations, and \n wherein the intravenous injection of PCC sends signals to the patient's body to produce new cells that are healthy, thereby preventing the new cells from being affected by intracellular and extracellular damaging signals.

Metadata:
- Claim Count in Document: 27.0
- Percentile: 100.0
- Lexical Diversity: 1.69565
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15090033', '15278699', '14056363', '13633057', '12842944']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6995982193124107
- 35 USC 102 Novelty (BERT): 0.5445595625521614
- Combined Prediction Score: 0.6840943536363858
- Mean Citation Score: 220.655234
- Max Citation Score: 441.10236
- Similarity Product: 231.94607680699824

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test